Decreased tumour MGMT mRNA levels, as well as catalytic activity of the β5 and β1 subunits were found in tumours from these BTZ+TMZ 164 mg/m2 treated animals, confirming bioactivity and target inhibition at the orthotopic site. The gene discussed is MGMT; the disease is neoplasm.